Related Experiment Videos
Naftidrofuryl in intermittent claudication: a retrospective analysis
1Department of Computer Science and Statistics, Faculte Universitaire de Mons, Belgium.
Journal of Cardiovascular Pharmacology
|January 1, 1994
Summary
Naftidrofuryl treatment significantly improved walking distance and reduced cardiovascular events in patients. This suggests potential for delaying or preventing surgery, impacting healthcare resource utilization.
Area of Science:
- Pharmacology
- Clinical Trials
- Cardiovascular Medicine
Background:
- Peripheral artery disease (PAD) management often involves improving walking capacity.
- Naftidrofuryl is a vasodilator investigated for intermittent claudication.
- Evidence on naftidrofuryl's efficacy and safety in a pooled analysis is needed.
Purpose of the Study:
- To retrospectively analyze pooled data from five clinical trials of naftidrofuryl at 600 mg daily.
- To evaluate the effect of naftidrofuryl on pain-free walking distance (PFWD) and cardiovascular critical events.
- To assess the influence of risk factors on treatment outcomes.
Main Methods:
- Retrospective analysis of 888 patients (447 naftidrofuryl, 441 placebo) from five published trials.
- Intention-to-treat analysis of success/failure outcomes and change in PFWD.
- Analysis of cardiovascular critical events and influence of risk factors.
Main Results:
- Naftidrofuryl significantly improved outcomes (p = 0.003) and PFWD (p < 0.002) compared to placebo.
- No significant influence of risk factors on PFWD changes was observed.
- Significantly fewer cardiovascular critical events occurred in the naftidrofuryl group (p = 0.029).
Conclusions:
- Naftidrofuryl (600 mg daily) demonstrates efficacy in improving walking distance and reducing cardiovascular events.
- The drug may postpone or reduce the need for surgery, particularly cardiovascular interventions.
- Findings have implications for optimizing healthcare resource allocation in PAD management.